Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Pembro+Chemo in Brain Mets
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
- Status
- TERMINATED
- Phase
- PHASE2
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3